(Total Views: 334)
Posted On: 12/12/2019 9:30:51 AM
Post# of 145248
I agree , even NASH study should go faster , because pre-clinical results look very good , and the most important no serious side effects ...
What we have here with Leronlimab is very unusual ...
IMO as always..
What we have here with Leronlimab is very unusual ...
IMO as always..
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)